{"id":"W2601086841","doi":"10.1200/jco.2014.32.15_suppl.8051","title":"A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; ERBB3; Progression-free survival; Log-rank test; Epidermal growth factor receptor; Cancer; Chemotherapy; Survival analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001983488,0.002040234,0.001894629,0.0005264379,0.0003528784,0.0009451448,0.0008117793,0.001549677,0.005178342],"category_scores_gemma":[0.001270026,0.0006581603,0.00124897,0.0003543139,0.001012787,0.001183857,0.0006162499,0.002345733,0.0009765998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009413877,"about_ca_system_score_gemma":0.001276323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004875673,"about_ca_topic_score_gemma":0.001271478,"domain_scores_codex":[0.9993118,0.0003905559,0.00002823522,0.000117068,0.00004196325,0.0001103724],"domain_scores_gemma":[0.9993457,0.0001214263,0.0001631358,0.00006133359,0.00003807494,0.0002702766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9675994,0.01165353,0.001471004,0.0001650947,0.0003483146,0.00005783422,0.00004928453,0.000494805,0.004196541,0.0001207823,0.0009344422,0.01290898],"study_design_scores_gemma":[0.8829347,0.1130002,0.002169017,0.000008645578,0.0001430604,0.00005714288,0.0000156817,0.0004111871,0.0005088997,0.0001324536,0.0006067753,0.00001225228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884857,0.001073361,0.0005880007,0.0005212095,0.0002259599,0.005691054,0.001331944,0.0001028377,0.001979896],"genre_scores_gemma":[0.9850314,0.0007168541,0.001434952,0.001138149,0.0002871076,0.006623942,0.001972586,0.00002581988,0.002769186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005178342,"threshold_uncertainty_score":0.01732326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.12330918582681,"score_gpt":0.5359127661219609,"score_spread":0.4126035802951509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}